Kyowa Kirin Ziftomenib Frontline AML clinical trial results from the frontline arm of the Phase 1 KOMET-007 study show significant efficacy in combination with intensive chemotherapy. In a joint announcement by Kura Oncology, Inc. and Kyowa Kirin Co., Ltd., updated data evaluating the oral menin inhibitor ziftomenib in combination with cytarabine plus daunorubicin (7+3) has been accepted for an oral presentation at the upcoming 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. The presentation will feature an extensive 99-patient dataset with extended follow-up in newly diagnosed patients suffering from NPM1-mutant (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML).
The comprehensive dataset represents one of the largest clinical analyses reported to date, examining the Kyowa Kirin Ziftomenib Frontline AML regimen combined with intensive induction chemotherapy. Based on the abstract data cut-off recorded on January 16, 2026, the updated analysis shows consistently high composite complete response (CRc) rates alongside exceptional depths of measurable residual disease (MRD) negativity across both targeted genetic molecular subtypes. These outcomes highlight the treatment’s capacity to induce profound, durable responses in newly diagnosed patients facing severe hematologic malignancies.
According to official company communications, the clinical findings highlight robust response durability, with the median duration of composite complete response not being reached in the NPM1-m patient cohort at an extended median follow-up of approximately 15 months. For patients seeking additional context on global pipeline developments, the authoritative Kyowa Kirin Pipeline internal page provides relevant corporate insights on ongoing clinical oncology assets.
High Efficacy Reflected in Kyowa Kirin Ziftomenib Frontline AML Data
The therapeutic combination evaluated in the Phase 1 KOMET-007 study demonstrated a CRc rate of 96% (47 out of 49 patients) specifically within the NPM1-m subgroup. In parallel, a CRc rate of 90% (45 out of 50 patients) was achieved in the KMT2A-r molecular subgroup. These metrics demonstrate the immense potential of the Kyowa Kirin Ziftomenib Frontline AML therapeutic strategy. Furthermore, deep molecular responses were verified, with MRD-negativity rates among CRc responders reaching 83% for NPM1-m and 82% for KMT2A-r AML, pointing to a clearing of leukemic cells at sub-microscopic levels.
From a clinical safety perspective, long-term administration revealed a highly consistent and manageable safety profile across both genetic subsets, without any new or unexpected safety signals appearing during extended follow-up. This supportive safety profile allows the combination regimen to be smoothly incorporated alongside intensive induction protocols without worsening toxicities. Dr. Mollie Leoni, Chief Medical Officer of Kura Oncology, noted that this extensive dataset supports the potential of the regimen to become a foundational backbone for frontline AML therapeutic management. To maintain a clear perspective on international corporate news, readers can access the primary Kyowa Kirin News Releases directory for corresponding institutional statements.
The successful expansion of this therapeutic combination has directly paved the way for the ongoing registrational Phase 3 KOMET-017 trial, which is currently actively enrolling patients. This Phase 3 trial evaluates ziftomenib in combination with both intensive and non-intensive chemotherapy regimens to firmly establish its regulatory path toward an anticipated accelerated FDA review target in 2028.
Future Clinical Milestones for Kyowa Kirin Ziftomenib Frontline AML
As ziftomenib (commercially marketed as KOMZIFTI™ in the United States) continues to show exceptional clinical promise in frontline settings, its established background remains a critical driver of authority. The drug is currently approved by the U.S. Food and Drug Administration for adult patients dealing with relapsed or refractory AML possessing a susceptible NPM1 mutation who lack alternative treatment options. The current data progression indicates that moving this once-daily oral menin inhibitor earlier into the treatment continuum could transform frontline standards of care.
The collaboration between Kura Oncology and Kyowa Kirin underscores a shared multi-decade commitment to precision medicine, highlighted by the emerging Kyowa Kirin Ziftomenib Frontline AML data. Updated data presentations at the upcoming congress will encompass longer median follow-up periods, central MRD evaluations, and deeper characterizations of hematologic recovery timelines. These developments are poised to validate the strategic expansion of menin inhibition across broader hemato-oncology indications globally.
Clinical Efficacy Results of Ziftomenib + 7+3 Combination (KOMET-007 Trial)
| Molecular Subtype Cohort | Patient Count (N) | Composite Complete Response (CRc) Rate | MRD-Negativity Rate among CRc Responders | Median Follow-Up (Months) | Median Duration of CRc |
| NPM1-mutant (NPM1-m) | 49 | 96% (47/49) | 83% (39/47) | 14.9 months | Not Reached |
| KMT2A-rearranged (KMT2A-r) | 50 | 90% (45/50) | 82% (32/39) | 9.3 months | 11.2 months |
